Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
COMPLETED
NCT07622004
PHASE3

Evaluate the Efficacy and Safety of INI101 Compared to BOTOX® in Subjects With Moderate to Severe Glabellar Lines.

Sponsor: INIBIO Co., Ltd.

View on ClinicalTrials.gov

Summary

To evaluate the efficacy and safety of botulinum toxin type A for injection INI101 compared to BOTOX® in subjects with moderate to severe glabellar lines.

Official title: A Multi-center, Double-blind, Randomized, Parallel, Active-controlled Phase III Trial to Evaluate the Efficacy and Safety of Botulinum Toxin Type A for Injection INI101 Compared to BOTOX® in Subjects With Moderate to Severe Glabellar Lines.

Key Details

Gender

All

Age Range

19 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

292

Start Date

2021-05-27

Completion Date

2022-03-05

Last Updated

2026-06-02

Healthy Volunteers

Yes

Conditions

Interventions

DRUG

Botulinum Toxin Type A Injection [INI101]

Single administration, Day 0, 20 units

DRUG

Botulinum Toxin Type A Injection [Botox]

Single administration, Day 0, 20 units

Locations (1)

INIBIO Co., Ltd.

Bucheon-si, Gyeonggi-do, South Korea